I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.Eli Lilly ( LLY ) entered 2026 with strong momentum across the board. Its share price has ...

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with Harmony Biosciences Holdings, Inc. (HRMY) identified as a strong candidate due to its favorable growth metrics and Zacks Rank [2][10]. Group 1: Earnings Growth - Harmony Biosciences has a historical EPS growth rate of 13.1%, but projected EPS growth for this year is significantly higher at 26.7%, surpassing the industry average of 13% [4]. - Double-digit earnings growth is a key indicator for growth investors, suggesting strong future prospects and potential stock price increases [3]. Group 2: Cash Flow Growth - The company currently exhibits a year-over-year cash flow growth of 10%, which is notably higher than the industry average of -4.5% [5]. - Over the past 3-5 years, Harmony Biosciences has achieved an annualized cash flow growth rate of 25.7%, compared to the industry average of 4.1% [6]. Group 3: Earnings Estimate Revisions - Recent upward revisions in current-year earnings estimates for Harmony Biosciences indicate a positive trend, with the Zacks Consensus Estimate increasing by 7.5% over the past month [8]. - The correlation between earnings estimate revisions and stock price movements supports the potential for near-term price appreciation [7]. Group 4: Overall Assessment - Harmony Biosciences has achieved a Zacks Rank of 1 (Strong Buy) and a Growth Score of B, indicating its potential as an outperformer and a solid choice for growth investors [10].

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, particularly in the financial sector, to achieve exceptional returns, although identifying such stocks can be challenging due to inherent volatility and risks [1] Group 1: Growth Stock Identification - The Zacks Growth Style Score system simplifies the identification of promising growth stocks by analyzing real growth prospects beyond traditional metrics [2] - AAR (AIR) is highlighted as a recommended stock with a favorable Growth Score and a top Zacks Rank, indicating strong growth potential [2] Group 2: Earnings Growth - Earnings growth is a critical factor for growth investors, with double-digit growth being particularly attractive as it signals strong future prospects [3] - AAR has a historical EPS growth rate of 26.7%, with projected EPS growth of 24% this year, surpassing the industry average of 20.8% [4] Group 3: Cash Flow Growth - Higher-than-average cash flow growth is essential for growth-oriented companies, allowing them to expand without relying on external funding [5] - AAR's year-over-year cash flow growth stands at 23.7%, exceeding the industry average of 18.6% [5] - The company's annualized cash flow growth rate over the past 3-5 years is 10.7%, compared to the industry average of 8.3% [6] Group 4: Earnings Estimate Revisions - Positive trends in earnings estimate revisions correlate strongly with near-term stock price movements, making them a valuable metric for assessing stock potential [7] - AAR's current-year earnings estimates have been revised upward, with the Zacks Consensus Estimate increasing by 4.7% over the past month [8] Group 5: Conclusion - AAR's combination of upward earnings estimate revisions and a Growth Score of A positions it as a potential outperformer and a solid choice for growth investors, reflected in its Zacks Rank of 2 [10]

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks ...

How Expensive Is Tesla Stock?CONCLUDED[Tesla Stock Falls After Earnings. The Stock Is All About AI Now.]Last Updated:---1 day ago# How Expensive Is Tesla Stock?By[Al Root]Tesla stock is pricey and volatile–two reasons traders and investors follow it so closely.Currently, Tesla trades for about 200 times earnings expected over the coming 12 months. It's the most expensive stock in the S&P 500. (Five companies aren't expected to produce profits over that span, according to FactSet.)Palantir is the second most ...

Core Insights - The U.S. equity markets showed optimism due to potential monetary easing and strong AI-related earnings, but sentiment cooled later in the quarter [1] - The Meridian Contrarian Fund delivered a net return of 2.18% in Q4 2025, underperforming both the Russell 2500 Index (2.22%) and the Russell 2500 Value Index (3.15%) [1] - The firm is focusing on systematic investment strategies to identify opportunities amid macroeconomic uncertainties, particularly with a new Fed Chair and high valuations in AI investments [1] Company-Specific Insights - The Honest Company, Inc. (NASDAQ:HNST) was highlighted as a leading detractor, with a one-month return of -3.10% and a 52-week loss of 60.19% [2] - As of January 27, 2026, The Honest Company, Inc. had a stock price of $2.50 and a market capitalization of $279.477 million [2] - The company is focusing on natural baby-care products and has made strategic decisions to exit less profitable markets, which the firm views positively for long-term growth potential [3]

Core Insights - Celldex Therapeutics is focused on developing antibody-based therapies for allergic, inflammatory, and autoimmune diseases, with a market capitalization of $1.76 billion [3] - The lead program, barzolvolimab, has shown promising results in clinical trials for chronic urticaria conditions, with significant efficacy and safety profiles reported [2][5] - The company is currently in a strong financial position with $583.2 million in cash and equivalents, expected to sustain operations until 2027 despite reporting a net loss of $67 million in Q3 [5] Clinical Development - Celldex initiated a global Phase 3 study for barzolvolimab in December, targeting ColdU and SD, with ongoing Phase 2 studies for prurigo nodularis and atopic dermatitis [1] - Positive Phase 2 results for barzolvolimab indicated that 66% of ColdU patients and 49% of SD patients achieved complete responses at 20 weeks, significantly outperforming placebo [2] - The company is also developing CDX-622, a bispecific antibody, with positive Phase 1 data and further results expected in Q3 2026 [1] Market Potential - There are over half a million patients in the U.S. and Europe suffering from various urticaria conditions, indicating a substantial unmet medical need that barzolvolimab could address [7] - Analysts have a favorable outlook on CLDX stock, with 13 out of 17 rating it a "Strong Buy" and an average target price suggesting a potential upside of 104% from current levels [7] Investment Landscape - The biotech sector, particularly for growth stocks like Celldex, is characterized by high risk and potential for significant returns based on clinical trial outcomes and regulatory approvals [4][6] - Celldex's stock performance is closely tied to the success of its clinical trials, typical for clinical-stage biotech companies [6]

For the past five years, investors who have stayed entirely invested in the highest-growth stocks in the market (and some of the largest-capitalization stocks in their sectors, for that matter) have outperformed. ...

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying those that can fulfill their potential is challenging [1] Group 1: TE Connectivity Overview - TE Connectivity (TEL) is currently recommended as a growth stock by the Zacks Growth Style Score system, which evaluates a company's genuine growth prospects [2] - The stock has a favorable Growth Score and a top Zacks Rank, indicating strong potential for performance [2] Group 2: Earnings Growth - Earnings growth is crucial for investors, with double-digit growth being particularly desirable as it signals strong future prospects [4] - TE Connectivity has a historical EPS growth rate of 8.4%, but projected EPS growth for this year is 24.8%, surpassing the industry average of 23.9% [5] Group 3: Asset Utilization - The asset utilization ratio, or sales-to-total-assets (S/TA) ratio, is an important metric for growth stocks, reflecting how efficiently a company generates sales from its assets [6] - TE Connectivity's S/TA ratio is 0.73, indicating it generates $0.73 in sales for every dollar in assets, which is better than the industry average of 0.72 [6] Group 4: Sales Growth - Sales growth is another critical factor, and TE Connectivity is expected to achieve a sales growth of 11.2% this year, compared to the industry average of 4.9% [7] Group 5: Earnings Estimate Revisions - Trends in earnings estimate revisions can validate a stock's performance potential, with positive revisions indicating favorable outcomes [8] - TE Connectivity's current-year earnings estimates have been revised upward, with the Zacks Consensus Estimate increasing by 3.6% over the past month [9] Group 6: Conclusion - TE Connectivity has achieved a Zacks Rank of 2 and a Growth Score of A, based on various favorable metrics, suggesting it is a strong candidate for growth investors [11]

Group 1 - The market environment has favored growth stocks over the past 15 years, leading to high valuations that traditional value investors find challenging [1] - Despite skepticism from analysts regarding the overvaluation of growth stocks, their prices have continued to rise due to strong business performance [1] - Aggressive value investors who shorted these growth stocks have faced significant losses [1] Group 2 - Harmony Biosciences (NASDAQ: HRMY) is a lesser-known biotech company that presents an attractive opportunity for traditional value investors [2] - The company has experienced business success that is not fully reflected in its stock price, warranting further investigation [2] - Harmony focuses on rare neurological disorders, an area with unmet treatment needs and less competition compared to more common diseases [6][5] Group 3 - The biotechnology sector often features stocks with high valuations based on future prospects, making attractively priced options like Harmony worth examining [7]